Literature DB >> 18458300

Eosinophilia among returning travelers: a practical approach.

Eyal Meltzer1, Ruth Percik, Joshua Shatzkes, Joshuah Shatzkes, Yehezkel Sidi, Eli Schwartz.   

Abstract

Eosinophilia is not uncommon among returning travelers; however, the optimal diagnostic and therapeutic approach in travelers, as opposed to immigrants and refugees, is not clearly established. This was a retrospective case series. All returning travelers from developing countries presenting at the post-travel clinic with eosinophilia (>or= 500 cells/mcl) during 1994-2006 were evaluated. Data were compared with other referrals to the post-travel clinic and with a random sample of a pre-travel clinic. Of the 955 returning travelers evaluated during the study period, 82 (8.6%) had eosinophilia, and 44 (4.4%) were diagnosed with schistosomiasis. Another 38 (4.2%) cases presented with non-schistosomal eosinophilia (NSE), among whom a definite parasitologic diagnosis was achieved in only 23.7%. However, an empiric course of albendazole led to a clinical improvement in 90% of NSE cases. Helminthic disease probably accounts for the majority of cases of post-travel eosinophilia. Empiric albendazole therapy should be offered to undiagnosed NSE patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458300

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  57-Year-old man with fever, rash, chronic watery diarrhea, cough, and sweats.

Authors:  Elfriede A Agyemang; Abinash Virk
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

2.  Newly Arrived African Migrants to Spain: Epidemiology and Burden of Disease.

Authors:  Joaquín Salas-Coronas; María Teresa Cabezas-Fernández; Ana Belén Lozano-Serrano; Manuel Jesús Soriano-Pérez; José Vázquez-Villegas; José Ángel Cuenca-Gómez
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

Review 3.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

4.  Eosinophilia in returning travelers and migrants.

Authors:  Stephan Ehrhardt; Gerd D Burchard
Journal:  Dtsch Arztebl Int       Date:  2008-11-14       Impact factor: 5.594

5.  Toxocariasis diagnosed in international travelers at the Institute of Tropical Medicine, Antwerp, Belgium, from 2000 to 2013.

Authors:  Steven Van Den Broucke; Kirezi Kanobana; Katja Polman; Patrick Soentjens; Marc Vekemans; Caroline Theunissen; Erika Vlieghe; Marjan Van Esbroeck; Jan Jacobs; Erwin Van Den Enden; Jef Van Den Ende; Alfons Van Gompel; Jan Clerinx; Emmanuel Bottieau
Journal:  PLoS Negl Trop Dis       Date:  2015-03-06

6.  A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia.

Authors:  Jean-François Magnaval; Guy Laurent; Noémie Gaudré; Judith Fillaux; Antoine Berry
Journal:  Mil Med Res       Date:  2017-05-23

7.  Low incidence of helminth infections (schistosomiasis, strongyloidiasis, filariasis, toxocariasis) among Dutch long-term travelers: A prospective study, 2008-2011.

Authors:  Femke W Overbosch; Tom van Gool; Amy Matser; Gerard J B Sonder
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

8.  Acute schistosomiasis in brazilian traveler: the importance of tourism in the epidemiology of neglected parasitic diseases.

Authors:  Diego Averaldo Guiguet Leal; Regina Maura Bueno Franco; Maria Francisca Neves; Luciana Franceschi Simões; Letícia Aparecida Duart Bastos; Silmara Marques Allegretti; Eliana Maria Zanotti-Magalhães; Luiz Augusto Magalhães
Journal:  Case Rep Infect Dis       Date:  2012-07-16

9.  Hypereosinophilia: Biological investigations and etiologies in a French metropolitan university hospital, and proposed approach for diagnostic evaluation.

Authors:  Martin Peju; Alban Deroux; Hervé Pelloux; Laurence Bouillet; Olivier Epaulard
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.